Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

Docetaxel has been approved by USFDA as a first-line treatment for castration-resistant prostate cancer (CRPC) patients. Patients receiving androgen deprivation therapy along with docetaxel result in superior ...

Source: Journal of Biomedical Science - February 23, 2022 Category: Biomedical Science Authors: Yu-Ke Fu, Bi-Juan Wang, Jen-Chih Tseng, Shih-Han Huang, Ching-Yu Lin, Ying-Yu Kuo, Tzyh-Chyuan Hour and Chih-Pin Chuu Tags: Research Source Type: research